Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
The batch will be distributed in India through a partner of RDIF and Panacea Biotec - Dr. Reddy's Laboratories
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Caspian Debt has in principle committed up to Rs 35 crores to SAMRIDH’s commercial debt investment pool
It strengthens its presence to over 250 stores
Investment of Rs 235 crores to add 411 beds in the next 18 months
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Anti-malaria API facility will be operational in 15-18 months
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
